Literature DB >> 21771909

Chemotherapeutic resistance: surviving stressful situations.

Luke A Gilbert1, Michael T Hemann.   

Abstract

Chemotherapeutic regimens involve the systemic administration of genotoxic compounds that induce cancer cell death via well-established DNA damage response signaling networks. Less understood is how the treatment of other cell types within the tumor microenvironment affects the therapeutic response. Here we discuss recent work that shows that tumor-adjacent cells can respond to genotoxic stress by activating a paracrine secretory program. Although this secretory response serves to protect progenitor cells and promote tissue regeneration in conditions of cellular stress, it can also be coopted by tumor cells to survive frontline chemotherapy. Thus, local prosurvival signaling may present a fundamental barrier to tumor clearance by genotoxic agents, suggesting that effective treatments need to target both cancer cells and the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771909      PMCID: PMC3148403          DOI: 10.1158/0008-5472.CAN-11-0277

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Mediastinal (thymic) large B-cell lymphoma: where do we stand?

Authors:  Thomas F E Barth; Frank Leithäuser; Stefan Joos; Martin Bentz; Peter Möller
Journal:  Lancet Oncol       Date:  2002-04       Impact factor: 41.316

Review 2.  Tissue repair and stem cell renewal in carcinogenesis.

Authors:  Philip A Beachy; Sunil S Karhadkar; David M Berman
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

3.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

4.  Viral IL-6-induced cell proliferation and immune evasion of interferon activity.

Authors:  Malini Chatterjee; Julie Osborne; Giovanna Bestetti; Yuan Chang; Patrick S Moore
Journal:  Science       Date:  2002-11-15       Impact factor: 47.728

Review 5.  The soluble interleukin 6 receptor: mechanisms of production and implications in disease.

Authors:  S A Jones; S Horiuchi; N Topley; N Yamamoto; G M Fuller
Journal:  FASEB J       Date:  2001-01       Impact factor: 5.191

6.  Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

Authors:  D E Cressman; L E Greenbaum; R A DeAngelis; G Ciliberto; E E Furth; V Poli; R Taub
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

7.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

Authors:  H Cavé; J van der Werff ten Bosch; S Suciu; C Guidal; C Waterkeyn; J Otten; M Bakkus; K Thielemans; B Grandchamp; E Vilmer
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

8.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.

Authors:  J M Adams; A W Harris; C A Pinkert; L M Corcoran; W S Alexander; S Cory; R D Palmiter; R L Brinster
Journal:  Nature       Date:  1985 Dec 12-18       Impact factor: 49.962

Review 9.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

10.  Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.

Authors:  M J Brisco; J Condon; E Hughes; S H Neoh; P J Sykes; R Seshadri; I Toogood; K Waters; G Tauro; H Ekert
Journal:  Lancet       Date:  1994-01-22       Impact factor: 79.321

View more
  25 in total

1.  Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.

Authors:  Rosalba D'Alessandro; Maria Grazia Refolo; Catia Lippolis; Nicola Carella; Caterina Messa; Aldo Cavallini; Brian Irving Carr
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-24       Impact factor: 3.333

2.  Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down.

Authors:  Chiara Arienti; Sara Pignatta; Michele Zanoni; Michela Cortesi; Alice Zamagni; Filippo Piccinini; Anna Tesei
Journal:  J Vis Exp       Date:  2017-12-11       Impact factor: 1.355

3.  Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis.

Authors:  Yi Seok Chang; Swati P Jalgaonkar; Justin D Middleton; Tsonwin Hai
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

4.  Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.

Authors:  Qiong Liu; Chris T Harvey; Hao Geng; Changhui Xue; Vivian Chen; Tomasz M Beer; David Z Qian
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

Review 5.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

Review 6.  Cellular and physiological roles for phospholipase D1 in cancer.

Authors:  Yi Zhang; Michael A Frohman
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

7.  Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.

Authors:  Liang Zhang; Jing Yang; Jianfei Qian; Haiyan Li; Jorge E Romaguera; Larry W Kwak; Michael Wang; Qing Yi
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

8.  TAK1 ubiquitination regulates doxorubicin-induced NF-κB activation.

Authors:  Li Liang; Yihui Fan; Jin Cheng; Da Cheng; Yanling Zhao; Baoshan Cao; Liwen Ma; Lei An; Wei Jia; Xu Su; Jianhua Yang; Hong Zhang
Journal:  Cell Signal       Date:  2012-09-07       Impact factor: 4.315

9.  1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diyl esters, a novel compound class with potent chemoreversal activity.

Authors:  Hsin-Yi Hung; Emika Ohkoshi; Masuo Goto; Kyoko Nakagawa-Goto; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem Lett       Date:  2012-10-13       Impact factor: 2.823

Review 10.  Beyond Tissue Stiffness and Bioadhesivity: Advanced Biomaterials to Model Tumor Microenvironments and Drug Resistance.

Authors:  Ankur Singh; Ilana Brito; Jan Lammerding
Journal:  Trends Cancer       Date:  2018-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.